Analysts Set Viridian Therapeutics, Inc. (NASDAQ:VRDN) PT at $42.43

Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) have been given a consensus recommendation of “Moderate Buy” by the fifteen brokerages that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and thirteen have given a buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $42.4286.

Several brokerages recently weighed in on VRDN. Royal Bank Of Canada increased their price target on Viridian Therapeutics from $41.00 to $45.00 and gave the stock an “outperform” rating in a research note on Thursday, November 6th. Evercore ISI restated an “outperform” rating and issued a $44.00 price objective on shares of Viridian Therapeutics in a research report on Tuesday, January 20th. William Blair assumed coverage on Viridian Therapeutics in a research report on Wednesday, December 3rd. They set an “outperform” rating for the company. The Goldman Sachs Group reissued a “buy” rating and set a $40.00 target price on shares of Viridian Therapeutics in a research note on Thursday, November 6th. Finally, BTIG Research restated a “buy” rating and issued a $61.00 price target on shares of Viridian Therapeutics in a research note on Tuesday, November 4th.

Insider Buying and Selling at Viridian Therapeutics

In related news, insider Jennifer Tousignant sold 2,272 shares of the firm’s stock in a transaction on Wednesday, December 31st. The shares were sold at an average price of $31.16, for a total transaction of $70,795.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.65% of the company’s stock.

Institutional Investors Weigh In On Viridian Therapeutics

Several large investors have recently made changes to their positions in VRDN. Aster Capital Management DIFC Ltd purchased a new stake in shares of Viridian Therapeutics in the third quarter worth about $35,000. Farther Finance Advisors LLC increased its stake in Viridian Therapeutics by 332.1% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,940 shares of the company’s stock worth $42,000 after acquiring an additional 1,491 shares during the last quarter. Bessemer Group Inc. raised its holdings in shares of Viridian Therapeutics by 947.7% during the 3rd quarter. Bessemer Group Inc. now owns 2,085 shares of the company’s stock worth $45,000 after acquiring an additional 1,886 shares in the last quarter. Larson Financial Group LLC bought a new position in shares of Viridian Therapeutics during the 3rd quarter valued at approximately $52,000. Finally, US Bancorp DE boosted its position in shares of Viridian Therapeutics by 23.2% during the 3rd quarter. US Bancorp DE now owns 2,457 shares of the company’s stock valued at $53,000 after acquiring an additional 463 shares during the last quarter.

Viridian Therapeutics Trading Up 2.4%

Viridian Therapeutics stock opened at $32.93 on Friday. Viridian Therapeutics has a 12-month low of $9.90 and a 12-month high of $34.29. The firm has a market capitalization of $3.14 billion, a price-to-earnings ratio of -10.90 and a beta of 0.90. The firm has a 50 day moving average of $31.70 and a 200 day moving average of $24.24. The company has a current ratio of 11.28, a quick ratio of 11.28 and a debt-to-equity ratio of 0.07.

Viridian Therapeutics (NASDAQ:VRDN) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.48. The business had revenue of $70.57 million during the quarter, compared to analyst estimates of $16.21 million. Viridian Therapeutics had a negative net margin of 426.58% and a negative return on equity of 78.50%. Viridian Therapeutics’s revenue was up 81993.0% on a year-over-year basis. As a group, research analysts predict that Viridian Therapeutics will post -4.03 earnings per share for the current year.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.